Structure, function and control of complement C5 and its proteolytic fragments

Current Molecular Medicine

Volumn 12, Issue 8, 2012, Pages 1083-1097

  Laursen, N S ^a   Magnani, F ^a   Gottfredsen, R H ^a   Petersen, S V ^a   Andersen, G R ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Anaphylatoxins; Complement; Immune evasion; Innate immunity; Pathogenesis; Structural biology

Indexed keywords

BETA ARRESTIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLUSTERIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5B; DIRECT LYTIC FACTOR; ECULIZUMAB; RETINA S ANTIGEN; VITRONECTIN;

ATHEROSCLEROSIS; BACTERIOLYSIS; CARBOXY TERMINAL SEQUENCE; COMPLEMENT ACTIVATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DEFENSE MECHANISM; DISEASE SEVERITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; MACROPHAGE; MAST CELL; MULTIPLE ORGAN FAILURE; MYASTHENIA GRAVIS; NEUTROPHIL; NONHUMAN; ORNITHODOROS MOUBATA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHAGOCYTOSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REPERFUSION INJURY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; X RAY CRYSTALLOGRAPHY;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C5; HUMANS; INFLAMMATION; KINETICS; MODELS, MOLECULAR; MUTATION; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84866551199     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412802480925     Document Type: Review

References (161)

1. Medzhitov R, Janeway CA, Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298-300.
2. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
3. Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol 2010; 28: 131-55.
4. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5: 981-6.
5. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-97.
6. Kojouharova M, Reid K, Gadjeva M. New insights into the molecular mechanisms of classical complement activation. Mol Immunol 2010; 47: 2154-60.
7. Gal P, Dobo J, Zavodszky P, Sim RB. Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions. Mol Immunol 2009; 46: 2745-52.
8. Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell Mol Med 2008; 12: 1074-84.
9. Pangburn MK, Ferreira VP, Cortes C. Discrimination between host and pathogens by the complement system. Vaccine 2008; 26 Suppl 8: I15-21.
10. Amara U, Flierl MA, Rittirsch D, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185: 5628-36.
11. Haeney MR, Ball AP, Thompson RA. Recurrent bacterial meningitis due to genetic deficiencies of terminal complement components (C5 and C6). Immunobiology 1980; 158: 101-6.
12. Peter G, Weigert MB, Bissel AR, Gold R, Kreutzer D, McLean RH. Meningococcal meningitis in familial deficiency of the fifth component of complement. Pediatrics 1981; 67: 882-6.
13. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 1984; 63: 243-73.
14. Snyderman R, Durack DT, McCarty GA, Ward FE, Meadows L. Deficiency of the fifth component of complement in human subjects. Clinical, genetic and immunologic studies in a large kindred. Am J Med 1979; 67: 638-45.
15. Morgan BP, Gasque P. Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol 1997; 107: 1-7.
16. Misumi Y, Oda K, Fujiwara T, Takami N, Tashiro K, Ikehara Y. Functional expression of furin demonstrating its intracellular localization and endoprotease activity for processing of proalbumin and complement pro-C3. J Biol Chem 1991; 266: 16954-9.
17. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J. The role of the anaphylatoxins in health and disease. Mol Immunol 2009; 46: 2753-66.
18. Lee H, Whitfeld PL, Mackay CR. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol Cell Biol 2008; 86: 153-60.
19. van Lookeren Campagne M, Wiesmann C, Brown EJ. Macrophage complement receptors and pathogen clearance. Cell Microbiol 2007; 9: 2095-102.
20. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991; 349: 614-7.
21. Bokisch VA, Muller-Eberhard HJ. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest 1970; 49: 2427-36.
22. Matthews KW, Mueller-Ortiz SL, Wetsel RA. Carboxypeptidase N: a pleiotropic regulator of inflammation. Mol Immunol 2004; 40: 785-93.
23. Nataf S, Davoust N, Ames RS, Barnum SR. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 1999; 162: 4018-23.
24. Okinaga S, Slattery D, Humbles A, et al. C5L2, a nonsignaling C5A binding protein. Biochemistry 2003; 42: 9406-15.
25. Siciliano SJ, Rollins TE, DeMartino J, et al. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci U S A 1994; 91: 1214-8.
26. Gerber BO, Meng EC, Dotsch V, Baranski TJ, Bourne HR. An activation switch in the ligand binding pocket of the C5a receptor. J Biol Chem 2001; 276: 3394-400.
27. Scola AM, Higginbottom A, Partridge LJ, et al. The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding. J Biol Chem 2007; 282: 3664-71.
28. Rasmussen SG, DeVree BT, Zou Y, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 2011; 477: 549-55.
29. Oldham WM, Hamm HE. How do receptors activate G proteins? Adv Protein Chem 2007; 74: 67-93.
30. Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007; 152: 429-48.
31. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 2010; 9: 373-86.
32. Giannini E, Brouchon L, Boulay F. Identification of the major phosphorylation sites in human C5a anaphylatoxin receptor in vivo. J Biol Chem 1995; 270: 19166-72.
33. Pollok-Kopp B, Huttenrauch F, Rethorn S, Oppermann M. Dynamics of protein kinase C-mediated phosphorylation of the complement C5a receptor on serine 334. J Biol Chem 2007; 282: 4345-53.
34. Braun L, Christophe T, Boulay F. Phosphorylation of key serine residues is required for internalization of the complement 5a (C5a) anaphylatoxin receptor via a betaarrestin, dynamin, and clathrin-dependent pathway. J Biol Chem 2003; 278: 4277-85.
35. Goodman OB, Jr., Krupnick JG, Santini F, et al. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 1996; 383: 447-50.
36. Laporte SA, Oakley RH, Zhang J, et al. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A 1999; 96: 3712-7.
37. DeFea KA. Beta-arrestins as regulators of signal termination and transduction: how do they determine what to scaffold? Cell Signal; 23: 621-9.
38. Naik N, Giannini E, Brouchon L, Boulay F. Internalization and recycling of the C5a anaphylatoxin receptor: evidence that the agonist-mediated internalization is modulated by phosphorylation of the C-terminal domain. J Cell Sci 1997; 110 (Pt 19): 2381-90.
39. Van Lith LH, Oosterom J, Van Elsas A, Zaman GJ. C5astimulated recruitment of beta-arrestin2 to the nonsignaling 7-transmembrane decoy receptor C5L2. J Biomol Screen 2009; 14: 1067-75.
40. Scola AM, Johswich KO, Morgan BP, Klos A, Monk PN. The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol 2009; 46: 1149-62.
41. Locati M, Torre YM, Galliera E, et al. Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines. Cytokine Growth Factor Rev 2005; 16: 679-86.
42. Chen NJ, Mirtsos C, Suh D, et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 2007; 446: 203-7.
43. Gerard NP, Lu B, Liu P, et al. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem 2005; 280: 39677-80.
44. Rittirsch D, Flierl MA, Nadeau BA, et al. Functional roles for C5a receptors in sepsis. Nat Med 2008; 14: 551-7.
45. Bamberg CE, Mackay CR, Lee H, et al. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem 2010; 285: 7633-44.
46. Tegla CA, Cudrici C, Patel S, et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res 2011; 51: 45-60.
47. Esser AF. The membrane attack complex of complement. Assembly, structure and cytotoxic activity. Toxicology 1994; 87: 229-47.
48. DiScipio RG, Linton SM, Rushmere NK. Function of the factor I modules (FIMS) of human complement component C6. J Biol Chem 1999; 274: 31811-8.
49. Esser AF, Kolb WP, Podack ER, Muller-Eberhard HJ. Molecular reorganization of lipid bilayers by complement: a possible mechanism for membranolysis. Proc Natl Acad Sci U S A 1979; 76: 1410-4.
50. Podack ER, Biesecker G, Kolb WP, Muller-Eberhard HJ. The C5b-6 complex: reaction with C7, C8, C9. J Immunol 1978; 121: 484-90.
51. Preissner KT, Podack ER, Muller-Eberhard HJ. The membrane attack complex of complement: relation of C7 to the metastable membrane binding site of the intermediate complex C5b-7. J Immunol 1985; 135: 445-51.
52. Shiver JW, Dankert JR, Esser AF. Formation of ionconducting channels by the membrane attack complex proteins of complement. Biophys J 1991; 60: 761-9.
53. McCloskey MA, Dankert JR, Esser AF. Assembly of complement components C5b-8 and C5b-9 on lipid bilayer membranes: visualization by freeze-etch electron microscopy. Biochemistry 1989; 28: 534-40.
54. Tschopp J, Muller-Eberhard HJ, Podack ER. Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature 1982; 298: 534-8.
55. Thai CT, Ogata RT. Complement components C5 and C7: recombinant factor I modules of C7 bind to the C345C domain of C5. J Immunol 2004; 173: 4547-52.
56. DiScipio RG. Formation and structure of the C5b-7 complex of the lytic pathway of complement. J Biol Chem 1992; 267: 17087-94.
57. Podack ER, Stoffel W, Esser AF, Muller-Eberhard HJ. Membrane attack complex of complement: distribution of subunits between the hydrocarbon phase of target membranes and water. Proc Natl Acad Sci USA 1981; 78: 4544-8.
58. MacKay SL, Dankert JR. Bacterial killing and inhibition of inner membrane activity by C5b-9 complexes as a function of the sequential addition of C9 to C5b-8 sites. J Immunol 1990; 145: 3367-71.
59. Harriman GR, Esser AF, Podack ER, et al. The role of C9 in complement-mediated killing of Neisseria. J Immunol 1981; 127: 2386-90.
60. Gee AP, Boyle MD, Borsos T. Distinction between C8-mediated and C8/C9-mediated hemolysis on the basis of independent 86Rb and hemoglobin release. J Immunol 1980; 124: 1905-10.
61. Whitlow MB, Ramm LE, Mayer MM. Penetration of C8 and C9 in the C5b-9 complex across the erythrocyte membrane into the cytoplasmic space. J Biol Chem 1985; 260: 998-1005.
62. Moskovich O, Fishelson Z. Live cell imaging of outward and inward vesiculation induced by the complement c5b-9 complex. J Biol Chem 2007; 282: 29977-86.
63. Podack ER, Kolb WP, Muller-Eberhard HJ. The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J Immunol 1978; 120: 1841-8.
64. Tschopp J, French LE. Clusterin: modulation of complement function. Clin Exp Immunol 1994; 97 Suppl 2: 11-4.
65. Heinen S, Hartmann A, Lauer N, et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009; 114: 2439-47.
66. Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144: 3478-83.
67. Kinoshita T, Takata Y, Kozono H, Takeda J, Hong KS, Inoue K. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. J Immunol 1988; 141: 3895-901.
68. Pangburn MK, Rawal N. Structure and function of complement C5 convertase enzymes. Biochem Soc Trans 2002; 30: 1006-10.
69. Takata Y, Kinoshita T, Kozono H, et al. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway. J Exp Med 1987; 165: 1494-507.
70. Daha MR, Fearon DT, Austen KF. C3 requirements for formation of alternative pathway C5 convertase. J Immunol 1976; 117: 630-4.
71. Hong K, Kinoshita T, Pramoonjago P, Kim YU, Seya T, Inoue K. Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D. J Immunol 1991; 146: 1868-73.
72. Vogt W, Schmidt G, Von Buttlar B, Dieminger L. A new function of the activated third component of complement: binding to C5, an essential step for C5 activation. Immunology 1978; 34: 29-40.
73. Rawal N, Pangburn MK. C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme. J Biol Chem 1998; 273: 16828-35.
74. Rawal N, Pangburn M. Formation of high-affinity C5 convertases of the alternative pathway of complement. J Immunol 2001; 166: 2635-42.
75. Rawal N, Pangburn MK. Formation of high affinity C5 convertase of the classical pathway of complement. J Biol Chem 2003; 278: 38476-83.
76. Kim YU, Carroll MC, Isenman DE, et al. Covalent binding of C3b to C4b within the classical complement pathway C5 convertase. Determination of amino acid residues involved in ester linkage formation. J Biol Chem 1992; 267: 4171-6.
77. Laursen NS, Andersen KR, Braren I, Spillner E, Sottrup-Jensen L, Andersen GR. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J 2011; 30: 606-16.
78. Wiesmann C, Katschke KJ, Yin J, et al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 2006; 444: 217-20.
79. Vogel CW, Fritzinger DC. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion. Toxicon 2010; 56: 1198-222.
80. Rawal N, Pangburn MK. Functional role of the noncatalytic subunit of complement C5 convertase. J Immunol 2000; 164: 1379-85.
81. Lachmann PJ, Halbwachs L. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol 1975; 21: 109-14.
82. Alper CA, Balavitch D. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science 1976; 191: 1275-6.
83. Vogel CW, Muller-Eberhard HJ. The cobra venom factordependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. J Biol Chem 1982; 257: 8292-9.
84. Fredslund F, Laursen NS, Roversi P, et al. Structure of and influence of a tick complement inhibitor on human complement component 5. Nat Immunol 2008; 9: 753-60.
85. Janssen BJ, Huizinga EG, Raaijmakers HC, et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005; 437: 505-11.
86. Fredslund F, Jenner L, Husted LB, Nyborg J, Andersen GR, Sottrup-Jensen L. The structure of bovine complement component 3 reveals the basis for thioester function. J Mol Biol 2006; 361: 115-27.
87. Nagar B, Jones RG, Diefenbach RJ, Isenman DE, Rini JM. X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. Science 1998; 280: 1277-81.
88. van den Elsen JM, Martin A, Wong V, Clemenza L, Rose DR, Isenman DE. X-ray crystal structure of the C4d fragment of human complement component C4. J Mol Biol 2002; 322: 1103-15.
89. Baxter RH, Chang CI, Chelliah Y, Blandin S, Levashina EA, Deisenhofer J. Structural basis for conserved complement factor-like function in the antimalarial protein TEP1. Proc Natl Acad Sci USA 2007; 104: 11615-20.
90. Andersen CB, Madsen M, Storm T, Moestrup SK, Andersen GR. Structural basis for receptor recognition of vitamin-B(12)-intrinsic factor complexes. Nature 2010; 464: 445-8.
91. Bramham J, Thai CT, Soares DC, Uhrin D, Ogata RT, Barlow PN. Functional insights from the structure of the multifunctional C345C domain of C5 of complement. J Biol Chem 2005; 280: 10636-45.
92. Rooijakkers SH, Wu J, Ruyken M, et al. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol 2009; 10: 721-7.
93. Sandoval A, Ai R, Ostresh JM, Ogata RT. Distal recognition site for classical pathway convertase located in the C345C/netrin module of complement component C5. J Immunol 2000; 165: 1066-73.
94. Zhang X, Boyar W, Toth MJ, Wennogle L, Gonnella NC. Structural definition of the C5a C terminus by twodimensional nuclear magnetic resonance spectroscopy. Proteins 1997; 28: 261-7.
95. Zuiderweg ER, Nettesheim DG, Mollison KW, Carter GW. Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data. Biochemistry 1989; 28: 172-85.
96. Cook WJ, Galakatos N, Boyar WC, Walter RL, Ealick SE. Structure of human desArg-C5a. Acta Crystallogr D Biol Crystallogr 2010; 66: 190-7.
97. Kawai M, Quincy DA, Lane B, Mollison KW, Luly JR, Carter GW. Identification and synthesis of a receptor binding site of human anaphylatoxin C5a. J Med Chem 1991; 34: 2068-71.
98. Toth MJ, Huwyler L, Boyar WC, et al. The pharmacophore of the human C5a anaphylatoxin. Protein Sci 1994; 3: 1159-68.
99. Hennecke M, Otto A, Baensch M, et al. A detailed analysis of the C5a anaphylatoxin effector domain: selection of C5a phage libraries on differentiated U937 cells. Eur J Biochem 1998; 252: 36-44.
100. Nikiforovich GV, Marshall GR, Baranski TJ. Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor. Biochemistry 2008; 47: 3117-30.
101. Fernandez HN, Hugli TE. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem 1978; 253: 6955-64.
102. Laursen NS, Gordon N, Hermans S, et al. Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus. Proc Natl Acad Sci USA 2010; 107: 3681-6.
103. Aleshin AE, Discipio RG, Stec B, Liddington RC. Crystal structure of C5b-6 suggests a structural basis for priming the assembly of the Membrane Attack Complex (MAC). J Biol Chem 2012; 287: 19642-52.
104. Hadders MA, Bubeck D, Roversi P, et al. Assembly and Regulation of the Membrane Attack Complex Based on Structures of C5b6 and sC5b9. Cell Rep 2012; 1: 1-8.
105. Janssen BJ, Christodoulidou A, McCarthy A, Lambris JD, Gros P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 2006; 444: 213-6.
106. Cooper NR, Muller-Eberhard HJ. The reaction mechanism of human C5 in immune hemolysis. J Exp Med 1970; 132: 775-93.
107. Shin HS, Pickering RJ, Mayer MM. The fifth component of the guinea pig complement system. 3. Dissociation and transfer of C5b, and the probable site of C5b fixation. J Immunol 1971; 106: 480-93.
108. Yamamoto KI, Lint TF, Gewurz H. Enhancement of C56-initiated lysis by cell-bound C3 fragments: evidence for a mechanism independent of the prior binding of C56 to C3b. J Immunol 1977; 119: 1346-50.
109. Hammer CH, Abramovitz AS, Mayer MM. A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components. J Immunol 1976; 117: 830-4.
110. Blom AM, Hallstrom T, Riesbeck K. Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol Immunol 2009; 46: 2808-17.
111. Serruto D, Rappuoli R, Scarselli M, Gros P, van Strijp JA. Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat Rev Microbiol 2010; 8: 393-9.
112. Joiner K, Brown E, Hammer C, Warren K, Frank M. Studies on the mechanism of bacterial resistance to complementmediated killing. III. C5b-9 deposits stably on rough and type 7 S. pneumoniae without causing bacterial killing. J Immunol 1983; 130: 845-9.
113. von Kockritz-Blickwede M, Konrad S, Foster S, Gessner JE, Medina E. Protective role of complement C5a in an experimental model of Staphylococcus aureus bacteremia. J Innate Immun 2009; 2: 87-92.
114. de Haas CJ, Veldkamp KE, Peschel A, et al. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med 2004; 199: 687-95.
115. Postma B, Poppelier MJ, van Galen JC, et al. Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J Immunol 2004; 172: 6994-7001.
116. Wright AJ, Higginbottom A, Philippe D, et al. Characterisation of receptor binding by the chemotaxis inhibitory protein of Staphylococcus aureus and the effects of the host immune response. Mol Immunol 2007; 44: 2507-17.
117. Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J Immunol 2005; 174: 2926-33.
118. Wines BD, Willoughby N, Fraser JD, Hogarth PM. A competitive mechanism for staphylococcal toxin SSL7 inhibiting the leukocyte IgA receptor, Fc alphaRI, is revealed by SSL7 binding at the C alpha2/C alpha3 interface of IgA. J Biol Chem 2006; 281: 1389-93.
119. Ramsland PA, Willoughby N, Trist HM, et al. Structural basis for evasion of IgA immunity by Staphylococcus aureus revealed in the complex of SSL7 with Fc of human IgA1. Proc Natl Acad Sci USA 2007; 104: 15051-6.
120. Hill HR, Bohnsack JF, Morris EZ, et al. Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J Immunol 1988; 141: 3551-6.
121. Cleary PP, Prahbu U, Dale JB, Wexler DE, Handley J. Streptococcal C5a peptidase is a highly specific endopeptidase. Infect Immun 1992; 60: 5219-23.
122. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
123. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9: 729-40.
124. Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol 2011; 48: 1631-42.
125. Okroj M, Heinegard D, Holmdahl R, Blom AM. Rheumatoid arthritis and the complement system. Ann Med 2007; 39: 517-30.
126. Ward PA. Sepsis, apoptosis and complement. Biochem Pharmacol 2008; 76: 1383-8.
127. Ward PA. The harmful role of c5a on innate immunity in sepsis. J Innate Immun 2010; 2: 439-45.
128. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1898-906.
129. Weissmann G. Pathogenesis of rheumatoid arthritis. J Clin Rheumatol 2004; 10: S26-31.
130. Linton SM, Morgan BP. Complement activation and inhibition in experimental models of arthritis. Mol Immunol 1999; 36: 905-14.
131. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92: 8955-9.
132. Lee H, Zahra D, Vogelzang A, et al. Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nat Biotechnol 2006; 24: 1279-84.
133. Grant EP, Picarella D, Burwell T, et al. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J Exp Med 2002; 196: 1461-71.
134. Woodruff TM, Strachan AJ, Dryburgh N, et al. Antiarthritic activity of an orally active C5a receptor antagonist against antigeninduced monarticular arthritis in the rat. Arthritis Rheum 2002; 46: 2476-85.
135. Vergunst CE, Gerlag DM, Dinant H, et al. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford) 2007; 46: 1773-8.
136. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420: 885-91.
137. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med 1999; 5: 788-92.
138. Laudes IJ, Chu JC, Sikranth S, et al. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 2002; 160: 1867-75.
139. Huber-Lang MS, Sarma JV, McGuire SR, et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J 2001; 15: 568-70.
140. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. The Lancet 2009; 373: 759-67.
141. Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 2011; 26: 41-57.
142. Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol 2006; 146: 294-302.
143. Fischetti F, Durigutto P, Macor P, Marzari R, Carretta R, Tedesco F. Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. Arthritis Rheum 2007; 56: 1187-97.
144. Lewis RD, Jackson CL, Morgan BP, Hughes TR. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. 2010; 47: 1098-105.
145. An G, Miwa T, Song W-l, et al. CD59 but not DAF deficiency accelerates atherosclerosis in female ApoE knockout mice. Arteriosclerosis & Thrombosis 2009; 46: 1702-9.
146. Cashman SM, Ramo K, Kumar-Singh R. A Non Membrane-Targeted Human Soluble CD59 Attenuates Choroidal Neovascularization in a Model of Age Related Macular Degeneration. PLoS One 2011; 6: e19078.
147. Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105: 1363-71.
148. Fondevila C, Shen X-d, Tsuchihashi S, et al. The Membrane Attack Complex (C5b-9) in Liver Cold Ischemia and Reperfusion Injury. Liver 2008; 42223: 1133-41.
149. Suhr BD, Black SM, Guzman-Paz M, Matas AJ, Dalmasso AP. Inhibition of the membrane attack complex of complement for induction of accommodation in the hamsterto-rat heart transplant model. Xenotransplantation 2007; 14: 572-9.
150. Wang Q, Rozelle AL, Lepus CM, et al. Identification of a central role for complement in osteoarthritis. Nat Med 2011; 17: 1674-9.
151. Armstrong C, Schubert J, Ueda E, et al. Affected paroxysmal nocturnal hemoglobinuria T lymphocytes harbor a common defect in assembly of N-acetyl-D-glucosamine inositol phospholipid corresponding to that in class A Thy-1-murine lymphoma mutants. J Biol Chem 1992; 267: 25347-51.
152. Hillmen P, Bessler M, Mason PJ, Watkins WM, Luzzatto L. Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1993; 90: 5272-6.
153. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73: 703-11.
154. Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993; 82: 1192-6.
155. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25: 1256-64.
156. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 1325-9.
157. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-3.
158. Hill A, Ridley SH, Esser D, et al. Protection of erythrocytes from human complement-mediated lysis by membranetargeted recombinant soluble CD59: a new approach to PNH therapy. Blood 2006; 107: 2131-7.
159. Gandhi J, Cashman SM, Kumar-Singh R. Soluble CD59 Expressed from an Adenovirus in vivo is a Potent Inhibitor of Complement Deposition on Murine Liver Vascular Endothelium. PLoS One 2011; 6: e21621.
160. Aleshin AE, Schraufstatter IU, Stec B, Bankston LA, Liddington RC, DiScipio RG. Structure of complement C6 suggests a mechanism for initiation and unidirectional, sequential assembly of membrane attack complex (MAC). J Biol Chem 2012; 287: 10210-22.
161. Williamson MP, Madison VS. Three-dimensional structure of porcine C5adesArg from 1H nuclear magnetic resonance data. Biochemistry 1990; 29: 2895-905.